23
Jul
2018
Tag: cancer
10
Jul
2018
Bionest
Precision Medicine and NGS Cancer Panels — ASCO Round-Up Part Two
As we wrote in our last post, precision medicine in oncology was the big theme of this year’s ASCO meeting. One of the key advances that has made possible this focus on treating cancer based on particular biomarkers expressed by a patient’s tumors, has been the advent of Next-Generation Sequencing (NGS)-based analysis of tumor DNA....
2
Jul
2018
Bionest
A Few Takeaways from ASCO 2018 — Part One
Precision medicine was an important theme of ASCO 2018 — the annual meeting of the American Society of Clinical Oncology — with this year’s meeting subtitled as “Delivering Discoveries, Expanding the Reach of Precision Medicine.” This theme was reflected not only in discussions around molecular profiling of patients, but also by the ever-increasing focus on...
21
May
2018
Bionest
Anticipating ASCO
We always greatly anticipate the scientific and educational sessions presented at the American Society of Clinical Oncology (ASCO) annual meeting, this year being held in Chicago from June 1-5. The meeting is the largest of its kind focused on cancer, attracting more than 30,000 oncology professionals from around the world to discuss ”state-of-the-art treatment modalities, new therapies,...
14
May
2018
Bionest
New Gains in Frontline Non-Small Cell Lung Cancer
Each spring, those of us who watch the oncology space turn our attention to two big U.S. meetings for the latest research news: the American Association of Cancer Research (AACR) annual scientific meeting, held in April, and the American Society of Clinical Oncology (ASCO), which will take place in June. AACR previously focused primarily on...
10
May
2018
Bionest
BIO2018, here we come: Real-time oncology and biomarkers for Alzheimer’s disease
The BIO International Convention is a huge gathering each year, as around 15-18,000 representatives from across industry and around the world get together to discuss policy, partnering, and product development over the course of four days. This year’s event, to be held in Boston from June 4 – 7, should be no exception. BIO has...
7
May
2018
Bionest
New Contender in Race to Develop Allogeneic CAR-T Treatments
Just months after negotiating the sale of autologous CAR-T pioneer Kite Pharma to Gilead for $11.9 billion, two of the executives who led Kite to success are back with a new company, a clinical-stage asset, and a portfolio of 16 preclinical therapeutic candidates, as well as substantial financing. This time, the focus is the development...
17
Apr
2018
Bionest
Moving from Exploratory Collaborations to Record-Setting Deals in IO
In early March, we wrote about the collaboration between Bristol-Myers Squibb and Nektar aimed at developing Nektar’s T-cell stimulating molecule NKTR-214 in combination with BMS’s checkpoint inhibitor Opdivo (nivolumab). That deal brought Nektar an eye-opening $1.85 billion in upfront cash and investments for a share of its development-stage drug, with the potential for an additional...
6
Mar
2018
Bionest
Setting (Financial) Records in I/O
On February 14, Bristol-Myers Squibb (BMS) and Nektar announced the largest-ever deal in history involving a single development-stage drug in a partnership that greatly expands combination testing of BMS’s checkpoint inhibitor Opdivo (nivolumab) and Nektar’s T-cell stimulating molecule NKTR-214. Many recent immuno-oncology collaborations have involved cost sharing but no other financial transactions, and the...
26
Feb
2018